NCT05360628View on ClinicalTrials.gov

Evaluation of PK and Safety of D-0120 and Allopurinol

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

February 10, 2022

Study Completion Date

July 23, 2022

Conditions
Healthy
Interventions
DRUG

D-0120 in combination with Allopurinol

noted above

Trial Locations (1)

53095

Spaulding Clinical, West Bend

Sponsors
All Listed Sponsors
lead

InventisBio Co., Ltd

INDUSTRY